Cargando…
Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries
Bevacizumab became the first molecular antibody to show survival benefit in advanced cervical cancer. In the GOG-0240 (Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer) trial, it improved overall survival...
Autores principales: | Gyawali, Bishal, Iddawela, Mahesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493276/ https://www.ncbi.nlm.nih.gov/pubmed/28717748 http://dx.doi.org/10.1200/JGO.2016.004895 |
Ejemplares similares
-
Managing menstruation in the workplace: an overlooked issue in low- and middle-income countries
por: Sommer, Marni, et al.
Publicado: (2016) -
Challenges to peer support in low- and middle-income countries during COVID-19
por: Mpango, Richard, et al.
Publicado: (2020) -
Prevention of cervical and breast cancer mortality in low- and middle-income countries: a window of opportunity
por: de Sanjose, Silvia, et al.
Publicado: (2019) -
Improving Cancer Outcomes In Low- and Middle-Income Countries
por: Love, Richard R.
Publicado: (2019) -
Introduction: Discovering Issues and Challenges in Low- and Middle-Income Countries
por: Ibrahim, Mohamed Izham Mohamed, et al.
Publicado: (2018)